by Nathaniel Harding | Sep 23, 2022 | Newsletters
Bottom Line Up Front (BLUF) In this month’s Doubleshot Newsletter, you will find: MoatBio Announces Successful Clinical Trials of Intranasal COVID-19 Vaccine Builder Highlight: OKC MED Week LP Highlight: Presbyterian Health Foundation Cortado’s Due Diligence Process...
by Nathaniel Harding | Sep 20, 2022 | Media
Moat Biotechnology Forms To Develop Novel Mucosal Vaccines for Covid-19 and Beyond: Announces Initial Funding Round and Promising Phase I trial results for Intranasal Covid-19 Vaccine OKLAHOMA CITY (Sept. 20, 2022) — Moat Biotechnology Corporation (MoatBio), a new...